CARDIOME PHARMA CORP - COM NO PAR (CRME)

CUSIP: 14159U301

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Equity / COM NO PAR
Total 13F shares
16,495,792
Share change
-1,101,948
Total reported value
$38,270,580
Price per share
$2.32
Number of holders
18
Value change
-$2,458,251
Number of buys
6
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 14159U301?
CUSIP 14159U301 identifies CRME - CARDIOME PHARMA CORP - COM NO PAR in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of CARDIOME PHARMA CORP - COM NO PAR (CRME) as of Q1 2018

As of 31 Mar 2018, CARDIOME PHARMA CORP - COM NO PAR (CRME) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 16,495,792 shares. The largest 10 holders included WESTFIELD CAPITAL MANAGEMENT CO LP, Stonepine Capital Management, LLC, PUTNAM INVESTMENTS LLC, Clough Capital Partners L P, Tamarack Advisers, LP, Rock Springs Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, JPMORGAN CHASE & CO, PNC Financial Services Group, Inc., and DEUTSCHE BANK AG\. This page lists 18 institutional shareholders reporting positions in this security for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.